Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting...

LXP Industrial Trust to Report Third Quarter 2024 Results and Host Conference Call November 6, 2024 WEST PALM BEACH, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LXP Industrial Trust (NYSE: LXP) (“LXP”), a real estate investment trust (REIT) focused on Class A warehouse and distribution real estate...

Progress Announces Third Quarter 2024 Financial Results Progress announces third quarter financial earnings for fiscal year 2024

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update - Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of...

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results - Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of...